Annual report pursuant to Section 13 and 15(d)

INCOME TAXES (Details Narrative)

v3.8.0.1
INCOME TAXES (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Income Tax Disclosure [Abstract]    
Federal statutory income tax rate 34.00% 34.00%
Expiration year 2037  
Net operating loss for income taxes purposes $ 1,481,000  
Income taxes expense $ 21,927
Valuation allowance 420,695 $ 43,904
Increase in valuation allowance $ 377,000  
Corporate tax rate, Description

The act replaced the prior-law graduated corporate tax rate, which taxed income over $10 million at 35%, with a flat rate of 21%.

 
United States loss before income taxes, Description

United States loss before income taxes is $1,433,074, which will not be included in the Company’s consolidated income tax return, because the Company owns only 60% of GenExosome. The U.S. tax law requires 80% ownership to consolidate.

 
Penalty $ 10,000